×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
INCY – incyte corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
INCY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/16
01:55 pm
incy
Incyte: Buy For The Turnaround, Stay For The Pipeline [Seeking Alpha]
Low
Report
Incyte: Buy For The Turnaround, Stay For The Pipeline [Seeking Alpha]
1/16
08:26 am
incy
Incyte's Pipeline Potential Signals Massive Upside For Investors [Seeking Alpha]
Low
Report
Incyte's Pipeline Potential Signals Massive Upside For Investors [Seeking Alpha]
1/15
11:56 am
incy
Factbox-Pharma sector doubles down on AI amid hopes of slashing costs, timelines [Yahoo! Finance]
Low
Report
Factbox-Pharma sector doubles down on AI amid hopes of slashing costs, timelines [Yahoo! Finance]
1/14
08:31 pm
incy
Earnings Preview: What To Expect From Incyte's Report [Yahoo! Finance]
Low
Report
Earnings Preview: What To Expect From Incyte's Report [Yahoo! Finance]
1/14
04:41 pm
incy
Why Incyte (INCY) Stock Is Trading Up Today [Yahoo! Finance]
Low
Report
Why Incyte (INCY) Stock Is Trading Up Today [Yahoo! Finance]
1/13
05:50 pm
incy
Incyte CEO Bill Meury: Blood cancer therapy development is company's central identity [CNBC]
Low
Report
Incyte CEO Bill Meury: Blood cancer therapy development is company's central identity [CNBC]
1/13
02:27 pm
incy
Incyte (NASDAQ:INCY) had its price target raised by analysts at TD Cowen from $101.00 to $128.00. They now have a "buy" rating on the stock.
Low
Report
Incyte (NASDAQ:INCY) had its price target raised by analysts at TD Cowen from $101.00 to $128.00. They now have a "buy" rating on the stock.
1/13
09:09 am
incy
Incyte (NASDAQ:INCY) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Incyte (NASDAQ:INCY) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/8
04:04 pm
incy
Form 4 INCYTE CORP For: Jan 06 Filed by: Issa Mohamed Khairie
Low
Report
Form 4 INCYTE CORP For: Jan 06 Filed by: Issa Mohamed Khairie
1/7
04:03 pm
incy
Form 4 INCYTE CORP For: Jan 05 Filed by: Stein Steven H
Medium
Report
Form 4 INCYTE CORP For: Jan 05 Filed by: Stein Steven H
1/7
04:01 pm
incy
Form 144 INCYTE CORP Filed by: Issa Mohamed Khairie
Medium
Report
Form 144 INCYTE CORP Filed by: Issa Mohamed Khairie
1/6
04:06 pm
incy
Form 144 INCYTE CORP Filed by: Iyengar Vijay K
Medium
Report
Form 144 INCYTE CORP Filed by: Iyengar Vijay K
1/5
04:34 pm
incy
Form 144 INCYTE CORP Filed by: Iyengar Vijay K
Medium
Report
Form 144 INCYTE CORP Filed by: Iyengar Vijay K
1/5
04:06 pm
incy
Form 4 INCYTE CORP For: Dec 31 Filed by: Clancy Paul J
Medium
Report
Form 4 INCYTE CORP For: Dec 31 Filed by: Clancy Paul J
1/5
04:06 pm
incy
Form 144 INCYTE CORP Filed by: Stein Steven H
Medium
Report
Form 144 INCYTE CORP Filed by: Stein Steven H
1/5
04:06 pm
incy
Form 4 INCYTE CORP For: Dec 31 Filed by: HARRIGAN EDMUND
Medium
Report
Form 4 INCYTE CORP For: Dec 31 Filed by: HARRIGAN EDMUND
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/5
Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream at the Revolutionizing Atopic Dermatitis Virtual Symposium
7.1%
7/30 Incyte Reports 2019 Second Quarter Financial Results and Provides Updates on Key Clinical Programs 6.4%
3/13 Incyte Co. (NASDAQ: INCY) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. They now have a $83.00 price target on the stock. 6.4%
3/26 Incyte Names New Member to Its Board of Directors 5.9%
1/13 Incyte Co. (NASDAQ: INCY) had its "buy" rating re-affirmed by analysts at Cowen Inc. 5.7%
11/25 Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 61st Annual ASH Meeting 5.3%
4/15 Form 4 INCYTE CORP For: Apr 13 Filed by: Pasquale Maria E 5.2%
2/18 Form 4 INCYTE CORP For: Feb 13 Filed by: Pasquale Maria E 4.0%
9/19 Form 4 INCYTE CORP For: Sep 18 Filed by: SWAIN PAULA J 4.0%
3/24 Blair likes Incyte in premarket analyst action [Seeking Alpha] 3.5%
7/30 Incyte Reports 2019 Second Quarter Financial Results and Provides Updates on Key Clinical Programs 6.4%
3/13 Incyte Co. (NASDAQ: INCY) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. They now have a $83.00 price target on the stock. 6.4%
3/26 Incyte Names New Member to Its Board of Directors 5.9%
1/13 Incyte Co. (NASDAQ: INCY) had its "buy" rating re-affirmed by analysts at Cowen Inc. 5.7%
11/25 Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 61st Annual ASH Meeting 5.3%
4/15 Form 4 INCYTE CORP For: Apr 13 Filed by: Pasquale Maria E 5.2%
2/18 Form 4 INCYTE CORP For: Feb 13 Filed by: Pasquale Maria E 4.0%
9/19 Form 4 INCYTE CORP For: Sep 18 Filed by: SWAIN PAULA J 4.0%
3/24 Blair likes Incyte in premarket analyst action [Seeking Alpha] 3.5%
TOP News Decliners
1/2
Incyte Announces Results of Phase 3 Study of Itacitinib in Patients with Treatment-Naïve Acute Graft-Versus-Host Disease
-9.4%
5/10 Form 4 INCYTE CORP For: May 09 Filed by: Iyengar Vijay K -6.1%
3/26 Form 8-K INCYTE CORP For: Mar 25 -5.6%
6/7 Form SC 13D/A INCYTE CORP Filed by: BAKER BROS. ADVISORS LP -5.0%
9/23 Incyte to Host Investor Conference Call from ESMO 2019 -4.6%
1/28 Incyte's skin disease drug meets main goal in late-stage study [Reuters] -3.8%
3/10 Incyte Joins Elite List Of Stocks With 95-Plus Composite Rating [Investor's Business Daily] -3.2%
9/27 Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma -3.2%
9/12 Incyte Co. (NASDAQ: INCY) is now covered by analysts at BMO Capital Markets. They set a "market perform" rating on the stock. -3.1%
8/27 BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019 -3.1%
5/10 Form 4 INCYTE CORP For: May 09 Filed by: Iyengar Vijay K -6.1%
3/26 Form 8-K INCYTE CORP For: Mar 25 -5.6%
6/7 Form SC 13D/A INCYTE CORP Filed by: BAKER BROS. ADVISORS LP -5.0%
9/23 Incyte to Host Investor Conference Call from ESMO 2019 -4.6%
1/28 Incyte's skin disease drug meets main goal in late-stage study [Reuters] -3.8%
3/10 Incyte Joins Elite List Of Stocks With 95-Plus Composite Rating [Investor's Business Daily] -3.2%
9/27 Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma -3.2%
9/12 Incyte Co. (NASDAQ: INCY) is now covered by analysts at BMO Capital Markets. They set a "market perform" rating on the stock. -3.1%
8/27 BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019 -3.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: